drugset / Trial / NCT01490632
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.
Timeline
- Start
- 2011-12
- Primary completion
- 2012-12
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 2 mg | Oral |
| Subject | Baricitinib | Small molecule | 4 mg | Oral |
| Subject | Baricitinib | Small molecule | 8 mg | Oral |
| Subject | Baricitinib | Small molecule | 10 mg | Oral |